Engineering a pathological tau-targeted nanochaperone for selective and synergetic inhibition of tau pathology in Alzheimer's Disease

Xu, Linlin; Ding, Yuxun; Ma, Feihe; Chen, Yue; Chen, Guidong; Zhu, Lin; Long, Jiafu; Ma, Rujiang; Liu, Yang; Liu, Jianfeng; Huang, Fan; Shi, Linqi

doi:10.1016/j.nantod.2022.101388

Cited by 25 publications

(15 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…1). 96 A tau protein-derived VQIINK peptide was modified on the surface of a self-assembled micelle, which was equipped with chaperone-like hydrophobic microdomains and confined spaces. 97 Owing to the unique surface structure, tau-nChap could escape from the lysosome and accumulate in the cytoplasm with high concentration.…”

Section: Recent Advances In Nanotechnology For Combating Admentioning

confidence: 99%

Recent advances in nanotechnology for combating Alzheimer's disease

et al. 2023

Mater. Chem. Front.

View full text Add to dashboard Cite

show abstract

Section: Recent Advances In Nanotechnology For Combating Admentioning

confidence: 99%

Recent advances in nanotechnology for combating Alzheimer's disease

et al. 2023

Mater. Chem. Front.

View full text Add to dashboard Cite

show abstract

“…An additional nanochaperone was developed by designing a VQIINK hexapeptide that was obtained from the tau protein onto the surface of a self-assembly micelle that was outfitted with chaperone-like hydrophobic microdomains and restricted spaces. This nanochaperone is able to collect pathogenic tau without affecting normal tau, and it inhibits their ability to aggregate by a significant amount because to the synergistic action of tau-recognizing peptides and limited hydrophobic microdomains on the surface ( Xu et al, 2022 ).…”

Section: Nanotechnology In Alzheimer’s Diseasementioning

confidence: 99%

The application of nanotechnology in treatment of Alzheimer’s disease

Cao

Zhang

2022

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

The buildup of beta-amyloid plaques in the brain results in Alzheimer’s disease (AD), a neurodegenerative condition. A permanent treatment for AD is not yet available. Only a slowing down of its advancement is possible with the current pharmaceutical options. Nevertheless, nanotechnology has proven to be advantageous in medical applications. It has a lot of potential for AD therapy, particularly in diagnosing the condition and providing an alternative course of treatment. In this review, we outline the developments and benefits of nanomedicines in treating AD. Prospective nanomedicines for diagnosing and surveillance therapeutic interventions for AD and other diseases of the central nervous system (CNS) may be clinically accessible, persuading the development of investigation in this field.

show abstract

“…The tau aggregation mechanism is still unknown; however, numerous findings suggest that aggregated tau acts as seeds that spread in a prion-like mechanism and trigger tau aggregation in surrounding cells ( Wischik et al, 2018 ; Xu et al, 2022 ). This prion-like mechanism suggests that abnormal tau “seeds” from the donor transfer to a recipient, causing the recipient to become abnormal and go on to act like a donor ( Wu et al, 2016 ).…”

Section: Alzheimer’s Diseasementioning

confidence: 99%

Perivascular spaces as a potential biomarker of Alzheimer’s disease

et al. 2022

View full text Add to dashboard Cite

Alzheimer’s disease (AD) is a highly damaging disease that affects one’s cognition and memory and presents an increasing societal and economic burden globally. Considerable research has gone into understanding AD; however, there is still a lack of effective biomarkers that aid in early diagnosis and intervention. The recent discovery of the glymphatic system and associated Perivascular Spaces (PVS) has led to the theory that enlarged PVS (ePVS) may be an indicator of AD progression and act as an early diagnostic marker. Visible on Magnetic Resonance Imaging (MRI), PVS appear to enlarge when known biomarkers of AD, amyloid-β and tau, accumulate. The central goal of ePVS and AD research is to determine when ePVS occurs in AD progression and if ePVS are causal or epiphenomena. Furthermore, if ePVS are indeed causative, interventions promoting glymphatic clearance are an attractive target for research. However, it is necessary first to ascertain where on the pathological progression of AD ePVS occurs. This review aims to examine the knowledge gap that exists in understanding the contribution of ePVS to AD. It is essential to understand whether ePVS in the brain correlate with increased regional tau distribution and global or regional Amyloid-β distribution and to determine if these spaces increase proportionally over time as individuals experience neurodegeneration. This review demonstrates that ePVS are associated with reduced glymphatic clearance and that this reduced clearance is associated with an increase in amyloid-β. However, it is not yet understood if ePVS are the outcome or driver of protein accumulation. Further, it is not yet clear if ePVS volume and number change longitudinally. Ultimately, it is vital to determine early diagnostic criteria and early interventions for AD to ease the burden it presents to the world; ePVS may be able to fulfill this role and therefore merit further research.

show abstract

Engineering a pathological tau-targeted nanochaperone for selective and synergetic inhibition of tau pathology in Alzheimer's Disease

Cited by 25 publications

References 40 publications

Recent advances in nanotechnology for combating Alzheimer's disease

Recent advances in nanotechnology for combating Alzheimer's disease

The application of nanotechnology in treatment of Alzheimer’s disease

Perivascular spaces as a potential biomarker of Alzheimer’s disease

Contact Info

Product

Resources

About